UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1612845 ...

Exhibit 99.1 Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update WATERTOWN, Mass. (May 9, 2024) – Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2024. "The topline data from AURORA, presented in April, strengthened our belief that bito ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________ Commission file number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1612845 (State or ...

Exhibit 99.1 Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Recent Business Highlights and Upcoming Milestones: Bitopertin: GlyT1 Inhibitor (Heme Synthesis Modulator) • Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 • On track to deliver multiple read-outs in 2024, including updated results from phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to___________ Commission file number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3220679 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39438 GEMINI THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Cha ...

Financial Performance - The company has not generated any revenue since inception and does not expect to do so in the near future[137]. - The net loss for the six months ended June 30, 2022, was $22.3 million, compared to a net loss of $35.5 million for the same period in 2021, an improvement of $13.2 million[163]. - The company reported net cash used in operating activities of $25.8 million for the six months ended June 30, 2022, compared to $30.9 million for the same period in 2021, a decrease of $5.1 million[168]. - Total operating expenses for the six months ended June 30, 2022, were $22.4 million, down from $32.8 million in 2021, a reduction of $10.4 million[158]. - Interest expense decreased to $0.1 million for the six months ended June 30, 2022, from $2.0 million in the same period of 2021, a decrease of $1.9 million[161]. - The accumulated deficit as of June 30, 2022, was $207.0 million[163]. - As of June 30, 2022, the company had cash and cash equivalents of $108.7 million, down from $137.0 million at the end of 2021[165]. - As of June 30, 2022, the company had cash and cash equivalents of $108.7 million, expected to fund operating expenses for at least the next twelve months[176]. - Net cash used in financing activities for the six months ended June 30, 2022, was $2.5 million, compared to $193.9 million provided in the same period of 2021[172]. Expenses - Research and development expenses are anticipated to decrease in 2022 compared to 2021 due to reduced clinical efforts and restructuring plans[140]. - General and administrative expenses are also expected to decrease in 2022 as compared to 2021 due to implemented restructuring plans[144]. - Research and development expenses decreased to $2.6 million for the three months ended June 30, 2022, from $10.8 million in the same period of 2021, a reduction of $8.2 million[155]. - General and administrative expenses were $4.7 million for the three months ended June 30, 2022, down from $5.5 million in 2021, a decrease of $0.8 million[156]. - The company anticipates a decrease in expenses for 2022 compared to 2021 due to reduced clinical efforts and restructuring implementations[174]. Merger and Strategic Plans - The company has entered into a merger agreement with Disc Medicine, Inc., with the transaction expected to close in Q4 2022, subject to stockholder approvals and customary closing conditions[122]. - The merger agreement includes potential termination fees of $3 million for the company and $7.8 million for Disc under certain circumstances[122]. - The company is highly dependent on the success of the proposed merger transaction with Disc, which is subject to shareholder approval[167]. - The company may explore strategic alternatives, including another strategic transaction or dissolution, if the merger with Disc is not completed[125]. - The Disc Merger Agreement was entered into on August 9, 2022, with the merger subject to stockholder approval and customary closing conditions[188]. Research and Development - The company has devoted substantially all efforts and financial resources to research and development activities since its inception in 2015[126]. - The company is working to advance GEM307 towards IND filing, which could be effective for treating systemic diseases[128]. - The company has not successfully completed any pivotal clinical trials or obtained regulatory approvals for its product candidates[127]. - The company recorded accrued expenses of approximately $0.8 million for expenditures incurred by contract research organizations (CROs) and contract manufacturing organizations (CMOs) as of June 30, 2022[187]. - The company may need to raise substantial additional funds to achieve business objectives, as product candidates may not achieve commercial success[175]. Financing and Capital Structure - The company entered into a term loan facility of up to $10.0 million, with $2.9 million principal outstanding as of June 30, 2022[181]. - The term loan matures in January 2023 and accrues interest at a floating rate, with a final end of term charge of 4.0% of the original principal amount[183]. - The company expects to finance operations through equity offerings, debt financings, and strategic alliances until substantial product revenue is generated[177]. Impact of COVID-19 - The ongoing COVID-19 pandemic has not significantly impacted the company's financial results in Q2 2022, but future impacts remain uncertain[130]. Company Classification - The company is classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of certain reduced disclosure obligations[194][195].